Last reviewed · How we verify
SRT2379
At a glance
| Generic name | SRT2379 |
|---|---|
| Sponsor | Sirtris, a GSK Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Effect of SRT2379 on Endotoxin-Induced Inflammation (PHASE1)
- Effect of Multiple Dose Levels of SRT2379 on Endotoxin-Induced Inflammation (PHASE1)
- A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2379 in Normal Healthy Male Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SRT2379 CI brief — competitive landscape report
- SRT2379 updates RSS · CI watch RSS
- Sirtris, a GSK Company portfolio CI